|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of New Mexico |
|---|---|
| Collaborator: |
Pfizer |
| Information provided by: | University of New Mexico |
| ClinicalTrials.gov Identifier: | NCT00375297 |
Purpose
This prospective double-blind, placebo-controlled (DBPC) study, assessed the efficacy of sildenafil in women with serotonin reuptake inhibitor antidepressant-associated sexual dysfunction (SRI-AASD) following the same protocol which previously established efficacy in men with SRI-AASD.
| Condition | Intervention | Phase |
|---|---|---|
|
Sexual Dysfunction Depression |
Drug: sildenafil |
Phase IV |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | Randomized Double Blind Placebo Controlled Study of Sildenafil for Treatment of Serotonergic Reuptake Inhibitor Associated Sexual Dysfunction in Women With Major Depression Treated to Remission |
| Estimated Enrollment: | 100 |
| Study Start Date: | January 2001 |
| Estimated Study Completion Date: | June 2005 |
This prospective double-blind, placebo-controlled (DBPC) study, assessed the efficacy of sildenafil in women with serotonin reuptake inhibitor antidepressant-associated sexual dysfunction (SRI-AASD) following the same protocol which previously established efficacy in men with SRI-AASD. Women (n=100) with MDD-remission and SRI-AASD were randomized to receive sildenafil (50-100mg) or placebo for 8 weeks, followed by 8-weeks open-label extension. Sexual function was assessed using the Clinical Global Impression-Sexual Function (CGI-SF), with positive response defined as a score <3, and UNM-SFI, ASEX, SFQ-FSD sexual function questionnaires. Depression was monitored using the HAM-D17. Hypothalamic-pituitary-adrenal-gonadal hormones were measured at baseline and DB-endpoint.
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:S Subjects will be females only, ages 18 to 50 years.
Subjects must meet at least one of the following criteria:
Clinically significant orgasm delay with masturbation or intercourse that according to patient opinion:
Exclusion Criteria:
Contacts and Locations| United States, New Mexico | |
| University of New Mexico Health Sciences Center | |
| Albuquerque, New Mexico, United States, 87131 | |
| Principal Investigator: | George Nurnberg, MD | University of New Mexico School of Medicine |
More Information
| Study ID Numbers: | 99321, Acc# 4-37011 |
| Study First Received: | September 11, 2005 |
| Last Updated: | September 8, 2006 |
| ClinicalTrials.gov Identifier: | NCT00375297 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
antidepressants sexual dysfunction women sildenafil |
PDE5 inhibitors serotonin reuptake inhibitor antidepressants women sildenafil |
|
Vasodilator Agents Neurotransmitter Agents Neurotransmitter Uptake Inhibitors Depression Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Enzyme Inhibitors Sildenafil Cardiovascular Agents Depressive Disorder |
Serotonin Uptake Inhibitors Pharmacologic Actions Behavioral Symptoms Phosphodiesterase Inhibitors Serotonin Agents Mental Disorders Therapeutic Uses Mood Disorders Central Nervous System Agents Antidepressive Agents |